All News

Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Breast cancer affected my looks and self-esteem, but I found small things could make a big difference in feeling pretty again.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with chemo, fewer were reported.

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

In the LEAP-015 trial, Keytruda and Lenvima plus chemo did not meet the primary end point of overall survival in HER2– gastroesophageal adenocarcinoma.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Having a life-threatening disease reminds me daily to make the most of whatever time I have.

Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.